(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.32%) $79.20
(-0.44%) $2.03
(0.20%) $2 314.30
(0.62%) $27.00
(0.57%) $968.10
(-0.08%) $0.931
(-0.16%) $10.97
(-0.14%) $0.797
(1.49%) $92.49
Live Chart Being Loaded With Signals
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...
Stats | |
---|---|
今日成交量 | 8.49M |
平均成交量 | 6.11M |
市值 | 13.60B |
EPS | CNY0 ( 2024-04-28 ) |
下一个收益日期 | ( CNY0 ) 2024-05-22 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -19.55 |
ATR14 | CNY0 (0.00%) |
音量 相关性
Shenzhen Hepalink 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Shenzhen Hepalink 相关性 - 货币/商品
Shenzhen Hepalink 财务报表
Annual | 2023 |
营收: | CNY5.42B |
毛利润: | CNY1.68B (30.90 %) |
EPS: | CNY-0.530 |
FY | 2023 |
营收: | CNY5.42B |
毛利润: | CNY1.68B (30.90 %) |
EPS: | CNY-0.530 |
FY | 2022 |
营收: | CNY7.16B |
毛利润: | CNY2.33B (32.61 %) |
EPS: | CNY0.500 |
FY | 2021 |
营收: | CNY6.37B |
毛利润: | CNY2.03B (31.94 %) |
EPS: | CNY0.164 |
Financial Reports:
No articles found.
Shenzhen Hepalink
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。